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HPV and cervical cancer in Moldova – 
epidemiological model with 
intervention’s cost – 
benefit/effectiveness analysis     
The Republic of Moldova has recently started battle with sexual health problems, but due to financial 
crisis, lack of program coordination, partly because of a lack of experience, sexually transmitted 
infections have still high morbidity and mortality. From latest ECDC reports Moldova is an European 
country with highest cervical cancer risk s classified by WHO in the field of sexually transmitted diseases 
at the level of countries of the third world. Additionally political transformation and beginning of social 
norm change in Moldova increase sexuality patterns – number of sexual partners (second demographic 
transition or post-modernist revolution). Computer simulations would answer some questions: when 
and with what probability should we expect a wave of such epidemic in Moldova. We would like to 
model multi-faceted transmission of diseases in the context of determining the best epidemiological 
control. There is also significant difference between urban and rural patterns (in terms of every 
important aspects of this study: demographic structure, health service access and sexuality). Key 
questions are to systematically collect and summarize relevant and current data on: 
-  HPV infections patterns, with type-specific HPV incidence, prevalence and clearance rates 
- The optimal preventive guidelines: cervical screening practice, targeted vaccination and sexual 
education 
- Costs of HPV vaccination, screening, treatment and preventive program. 
Science (as physics, mathematics and computer science) should take the responsibility of enhancing 
preventive health prevention strategies. We want decision makers to be informed about proposition of 
changes to be made in the allocation of the health resources required to implement optimal 
(cost/effective) prevention program. 
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Introduction of HPV/cervical cancer analysis  
Human papillomavirus, or HPV, is a sexually transmittable virus infection, which is not only the main, but 
also necessary risk factor for developing cervical cancer - first most common type of cancer in working 
age women in Moldova. The time between getting infected by HPV and developing a cancer can be 
twenty years or more, therefore a dynamic model of human behavior would be very useful, so that 
simulations can be made and different scenarios compared. We observe both behavioral change 
(sexuality increase) and demographical change (population ageing). Among the oncogenic HPVs, the 
most severe one is type 16, present in about half of all cervical cancer cases-we model one strain (16) 
and imitate multi-strains environment. A lot of medical data are used as model parameters. Recent 
studies have shown that the main safety precaution with respect to cervical cancer is going to be a 
combination of vaccination and screening - since only type specific vaccines (for type 16 and 18) are 
available and there are as many as 15 high risk HPVs. 
The main goal is the authoritative analysis of the costs and losses of potential epidemiological control 
strategies and identifies potential problems that health care will have to face in the future, 
● Very little data about sexual contacts (sensitive data), 
● There was no verified so far, working model of STI sexually transmitted infections dedicated to the 
Moldavian community. 
Cervical cancer in Moldova – some fact sheet assumption to model 
The Republic of Moldova is one of Europe's poorest nations. Total expenditure on health amounts to just 
150EUR per capita (10 times less than in Poland for example). The economic situation over the past 2 
decades has not allowed for health systems development and reliable data on cervical cancer were 
missing. Till now some statistics differ significantly dependently of data source. Demographically, 
Republic of Moldova had (in years 1998-2014) a population of 1.40-1.60 millions women ages 15 years 
and older who are at risk of developing cervical cancer. Sexual active woman cohort (age 15-65) was in 
range 1.25-1.35 millions. Last 10 years estimates indicate that every year 400-550 (approx data) women 
are diagnosed with cervical cancer and 145-220 (register data) die from the disease. Estimated society 
cost is around 6000 disability-adjusted life years (DALYs) every year (or 4000 QALY). Cervical cancer ranks 
as the 3rd most frequent cancer among women in Republic of Moldova and the 1st most frequent cancer 
among women between 15 and 44 years of age. The incidence of cervical cancer, had increased from 
2005 to 2009. It is 39.3% of all kind of woman cancer cases. Data on the HPV burden is not available, but 
generalizing old studies with data from other south-eastern Europe countries 15-20 % of women in the 
general population have HPV and 80-90% had it in their live. Prevalence of oncogenic HPV-16/18 is 
estimated on 2-5%. 
Fatal cases registry 
The only reliable data on cervical cancer in Moldova are death registry. However, provided model can 
predicted new cancer cases, so incidence is needed. 5 years Survival rates decease in last 10 years from 
70.4% in 2000 to 61.5% in 2011. Recent numbers in 2013: 2394 persons (58.7%) and in 2012: 2487 
(58.8%). 
 Figure 1 Death cases registry 
Fatal cases are not good estimators of incidence, because death is shifted in time from caner discovery, 
and mortality rates increase in time (over 10% in investigated period). Recently, in 2013 there were 198 
cases, but in 2012 only 165. Mortality also depend on age (survival chance is decreasing with age).  
 
 
Figure 2 Death cases in age cohorts 
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Incidence 
According do incomplete incidence estimation, we have reliable statistics since 2012, where 475 cases 
where register, but only 319 was categorized by age:  
Table 1 Confirmed case registry  
 
Base on such a incomplete information (we have detailed registered data only since 2012 and 30% of 
them were not categorized properly), we could only estimate magnitude of incidence, but it already 
shows some difference with western countries. As it was indicated, incidence rate was growing last 
decade (probably partly caused by huge development in surveillance and diagnosing system), while 
death cases were decreasing the same time (mostly due to better treatment). 
Demographics 
In our model we are interesting in sexual active (15-65 years old) part of population (with tracing older 
woman with HPV, who could develop cancer later on). Mentioned population was growing by last 15 
years till now, but because of negative natural growth rates it will suppose to decay in next 15 years. 
Society is ageing since around 2004 (indicate cancer rate follow this increase). We do not count 
Transdniestrian part of Moldova as well as migration, which is also not included. 
 
 
Figure 3 Amount of 15 years old teenagers entering sexual maturity age. Historical data and projection based on population 
structure in 2014 
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Sexuality 
First intercourse women age in Moldova (17-19) is significantly higher than in other Post-Communistic 
and also Western Europe countries. There are no sufficient information about partner exchange rate of 
adults, but some estimates as divorce patterns do not differ significantly from neighboring countries like 
Ukraine or Romania. We could assume, that outside of teenagers cohort, sexuality patterns will follow 
the same distribution as in neighboring countries. Moreover, typical for post-communistic countries 
liberalization of sexual life in the breakage of XX/XXI century, also took place, so we assume observing 
increase of sexuality. It affects mostly youngest, most susceptible to influence cohort. It start from 1991 - 
political transformation and beginning of social norm change in Moldova (second demographic transition 
or postmodernist revolution).  We do not know exactly how fast such an increase is, so we will test few 
scenarios of it.  
Screening 
Opportunistic screening was a rule in Moldova till 2011. Since 2011 Moldova introduced very novel and 
wide national program of common screening (women above 20 years old every 2 years). However, based 
on studies from 2013 around 70% adult women were never tested in their life, but more than 100 000 
tests were done the same year (1/10 of targeted population). At this point screening features shows up, 
that young, rich, educated women from Kishinev (who are in risk group for HPV infection) screen every 
two years, but old, poor, less educated woman from countryside (who are in risk group for cancer 
development) do not do that at all. 
Vaccination 
There is no public vaccination program as well, there is no money for that. There was pilot project in 
2012 financed by USAIDS, but based on non-governmental studies less than 5% of targeted girls were 
vaccinated (amount of vaccines given to Moldova suppose to cover 75% of targeted group). 
Brief model mathematical description 
Whole model description, parameters and sensitivity analysis will be further provided in Supplementary 
information. 
 
Figure 4 General type of modeling infectious diseases 
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 Figure 5 Overview over whole real model for imagination of complexity 
 
Figure 6 Model of Cervical cancer; for control:  a combination of vaccination and screening; and scenarios: demographic 
change, increase of sexuality, screening freq 
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Model preliminary results for HPV transmission and cancer development 
 
According to provided information, model for Moldova was proposed. It’s set of deterministic 
differential equations (implemented in Vensim). Stochasticity was introduced in sexual partner change 
rates. The model has aggregated the most important paths of infection for the most important 
pathogens. Main object is (Human Papilloma Virus, HPV) associated also with the occurrence of cervical. 
This is pathogen, with which has been already carefully analyzed, because its epidemiology has been 
widely described and modeled in recent years. We would like prepare cost/benefit analyze for different 
vaccination strategies, various screening programs and preventive programs (using condoms) for 
Moldova, based on its own demography and sexual behavior. We used data since 1998 to adjust model 
parameter and we project till 2031. We use mathematical and sociological concepts within complex 
system methodology. Mathematical modeling of infectious diseases transmitted by sexual contacts (e.g., 
HPV) is increasingly being used to determine the impact of possible interventions (there are  dozens of 
such studies in literature). The most unknown parameter is the sexuality distribution and its increase. 
That increase was introduced as a variable. Screening efficient intervals were also implemented as a 
variable. 
 
Table 2 Model scenarios labeling 
Levels Sexuality Screening frequencies 
0 10% linear increase in whole population                    
No additional sexuality increase in young cohorts (1,2) 
Obtaining 10 years effective 
interval 
1 10% linear increase in whole population              
Additional 10% of increase in young cohorts (1,2) 
5 years effective interval 
2 10% linear increase in whole population               
Additional 20% of increase in young cohort (1,2) 
3 years effective interval 
 
Age Groups in model: 
1) 15-19 (initiation of sexual live) 
2) 20-24 (most active sexual group) 
3) 25-34 (stabilization of sexual live) 
4) 35-64 (sexual stagnation and stronger susceptibility to cancer) 
5) >64 (no sexuality and cancer development) 
Incidence 
The yearly incidence rates is the goal of our project. Initial condition and some model parameter were 
adjust to obtain empirical shape (Figure 7). 
 Figure 7 Incidence of new cancer case estimated for historical data (1998-2012) and possible projections till 2031  
 
 
Figure 8 Incidence rates per 100k women (age 15-65) of new cancer case estimated for historical data (1998-2012) and 
possible projections till 2031  
 
 Figure 9 Developing cancer rates for different age groups   
Demographics 
In our model Moldovan sexual active population (working age) was increasing till year 2014, and  would 
be decreasing after.  It has been also aging  since around 2005. 
 
Figure 10 Population and gender structure of Moldova (projection) 
 Figure 11 Entering 15 years old rates per day for girls. Compare with (with Figure 3) 
 
Figure 12 Change of Moldovan women age distribution with time 
Sexuality 
We model sexuality starting from known form international studies distribution of sexuality. We assume 
intensively of partner change is on average  60% of EEA intensively (on the similar level as in Ukraine and 
Romania). Additionally, the sexuality of the youngest cohort is reduced next 30% (because of late first 
intercourse age). We try 3 levels of sexuality increase: 0-low, 1-medium, 2- high (Table 2). We assume 
random mixing between rural an urban populations, as well as random mixing between whole male 
population and different woman age-cohorts.  
 Figure 13 Sexuality increase within the youngest cohort 
Screening 
Change of screening procedures from opportunistic to regular is represented in effective screening 
frequencies. We try 3 levels of frequency decrease: 0-low, 1-medium, 2- high. The beginning of 
introducing national screening program produce huge positive test results, because women, who were 
colonized and never tested before are captured (treatment can be applied automatically). Having 
experience in similar screening program in central Europe, positive test results decease from initial 
values (just after introducing national program) above 10% till below 5% few years later. We assume, 
that standard cytology test (the cheapest) will be used. It has good sensitivity and specificity for 
persistent colonized women and some HPV positive are also captured. Estimated overall cost of one test 
is 5 EUR, while cost of cancer treatment is around 1000 EUR (without social cost of it).  
 
 
Figure 14 Screening frequencies changes 
Vaccination 
We assume small opportunistic vaccination (with increase) and pilot program in 2012. We assume, that 
up to 5% of girls will be voluntary vaccinated.  
 
Figure 15 Size of vaccinated cohort 15-19 
 
Conclusions and Discussion with cost/benefits approach 
Moldovan cervical cancer perspective seems to be much better, than in central/western Europe 
countries, because of relatively young society. Aging would not be a big issue (at least from HPV and 
Cervical Cancer perspective) in next 15 years (also comparing with central/western Europe countries). In 
such a preliminary setup obligatory vaccination seems to not be so crucial (for none of realistic scenarios 
increase of cancer cases is possible) for public health as in most countries in European Union. However, 
screening practice could be verified in terms of efficiency, when cost/benefit calculation would be done.  
Which screening guidelines are optimal? 
Screening 20 years old girls as well as very old ladies is very costly (if all of those categories of woman 
test regularly it would cost ~400k EUR yearly, in current reality less than 100k EUR), but usually do not 
have significant effect on population (prevalence rates of cytological changes are 10 times smaller than 
in <25 years old cohort). Screening ladies above 65 years old is also not so efficient because the mortality 
caused by than other factors is much higher. They are not productive any more and aging issues would 
more and more problematic in Moldova in next decades. 
 Figure 16 Mortality and incidence patterns comparison (based on https://www.hpvcentre.net) 
Moreover, public heath system in Moldova has no capacity to couple with official screening program, 
where more than 700k test suppose to be done yearly (currently it’s 100k and in many sites it seems to 
be already overloaded). It’s more then 3.5 M EUR yearly according to this theoretical program. We are 
assuming 1.5k EUR standard treatment cost of cervical cancer with additional (in case of younger 
women) 1k EUR socio/medical costs (for woman below 65 age treatment is more expensive and 
state/society pays bills like sick leave, children care, lost of tax incomes). We examine overall cancer 
costs (Figure 17) for actual screening program +20 and (scr2) and 25-64 (scr1) where time interval 
frequencies are represented by health care efficiency levels hc1 (medium – 5 year efficient intervals) and 
level hc2 (high – 3 year efficient intervals not obtained yet even in developed countries). The saving 
perspective in 10-15 years would in range 100-300k EUR yearly. We also observe strange pick in cost 
projections (Figure 17, Figure 19) around year 2020. It’s consequence of high velocity of screening 
interval adjusting to the national guidelines in the society. This is the point, when costs of screening exit 
benefits coming from reducing cancer cases. For example if we decrease effective screening intervals 
from every 12 years every 6 years, the cost of screening will rise twice. However,  3 years additional 
intervals decrease up to 3 years, makes program 4 times more expensive. This is known in economics as 
Laffer effect.  Screening cost will overcome since 2020-25 whole others costs of cervical cancer issue for 
most of scenarios.   
 Figure 17 Overall costs in EUR of cervical cancer (screening and treatment costs). Scr1 – optimal screening rules, Scr2-actual 
screening rules 
To get rid of those strange sharp picks, we could change screening function to more smooth (without 
sharp picks) and get more traditionally Laffel effect. 
 
Figure 18 Costs after smoothing procedure on screening frequency change 
Sexual education and targeted vaccination 
There is also problem with estimating sexuality risk factors. We assume, that infectivity is higher than in 
EEA states, because of less condom prevalence use. For viral infection like HIV, proper condom use 
reduce transmission probability per intercourse more than 10 times (for HPV not so many study were 
done, but it’s shown that reduction is at least more than 2 times).  Let consider intervention to teenagers 
age 15-19. The goal is to catch potential the most sexual active cohort (base on sociological studies 
according to first intercourse time, etc.) and vaccinate only 15-20% of girls with cheapest two dose 
vaccine (100EUR). Moreover, let introduce official sexual education (with convincing to condom use) 
with marginal costs (like 5EUR per each girl). In longer terms (like 30 years), that could be optimal 
national outcome from cancer incidence point (Figure 20) of view and the cost is very high only at the 
beginning of vaccination program introduction. 
 
Figure 19 Cost/Benefit analysis of preferential vaccination 
It seems, that targeted vaccination has similar costs in long perspective like frequent screening (compare 
total cost of scenarios hc1_no-vacc with hc0_vacc Figure 19) and population effect are also similar 
(compare number of new cases of scenarios hc1_no-vacc with hc0_vacc Figure 20). Thus, cancer 
treatment costs would be increasing with time, and vaccine suppose to be decreasing (unfortunately, it’s 
opposite at this moment), so vaccination could be even more profitable. 
  
Figure 20 Long-term new cases projections 
Despite of closed discussion about optimal HPV vaccination guidelines for developed countries (all girls 
below 14 years old), problem is still open in developing countries, where cost of such a action are too 
high (the newest generation of 3 dose vaccine could cost even 600EUR). Targeted vaccination could be 
consider, because costs are similar to high frequencies screening schema with the same cancer cases 
projection. However, some positive side effects of vaccination as reduction of pathogen circulation in 
society (Figure 21) will cause decrease of other pathologies related to HPV 18/16 like genital warts and 
other cancer (like anal). However, screening could be limited, but mustn’t be cancel, because: 1) vaccine 
doesn’t provide 100% immunity lifelong; 2) Another 10-30% of oncogenic HPV types are not stopped by 
vaccine. 
 
Figure 21 Effect of vaccination to reduce prevalence of HPV in whole society (example of males) 
Cost-effectiveness analysis 
Let consider more precise changes monetary and population effects of intervention.  To do so we 
introduce quality-adjusted life-year (QALY) - a measure of disease burden, including both the quality and 
the quantity of life lived. The QALY is based on the number of years of life and adjusted to health state 
(where 1 is a perfect health and 0 is death) that would be saved by the intervention. In previous chapters 
we proved, that compulsory, universal vaccination are too expensive respectively to Moldova GDP and 
disease will be decreasing any way - even with no interventions [Figure 7].  QALY indicates the best the 
benefits of intervention, because it is sensitive to current patient age (literally to current life expectancy).  
The intervention is cost-effective if it incremental cost per QALY yearly is below GDP per capita of given 
country (~2.5k EUR for Moldova) or it could be partly cost-effective if it’s below 3*GDP (~7.5k EUR for 
Moldova). 
Firstly, we compare screening scenarios. Here, we assume only two  effective frequencies, medium hc1 
its every 5 years and high hc2 – 3 years  approaching those limits by linear splines (Figure 14).  The most 
realistic scenario is hc1, because of it’s difficult to convince all the women to screen regularly and this 
level of intensively of test is within Moldova’s heath system capacity. The lost in cost of interventions 
between scr1 (our proposition) and scr2 (official realistic– yellow case in Figure 23) is around 300k EUR, 
and for total costs (including costs cancer curing) 250k EUR [Figure 23, Figure 22]. The gain in QALY is 
only 15 [Figure 23, Figure 22]. The Incremental QALY between scr1 and scr2 is 20k EUR per QALY, which 
is not cost-effective at all. If we compare theoretical  (hc2 orange case in Figure 23) official guides with 
realistic official  guides (hc1 yellow case in Figure 23), Incremental QALY is 1.5M/300=50k EUR per QALY. 
Beside hc2 is relatively good form population, it’s too costly for the society. 
 
Figure 22 Past and short term analysis of main interventions of only cruel factors as QALY and Intervention cost 
 
Another issue are targeted vaccinations. Recent studies have shown that the main safety precaution with 
respect to cervical cancer is going to be a combination of vaccination and screening (it’s already showed 
that optimal is scr1). There is still open questions about vaccination, while we already proved, that all 
converged vaccinations are not needed and too expensive. Here we propose targeted vaccination for 
20% potentially most sexually active. We choose, the cheapest 2 dose vaccine at age of 15. Within 
selection process, we must survey all girls of given age and we use this for sexual education (proper using 
condom reduces probability of infections by 50-99%  dependence of source).  For purpose of this 
research, we assume, that we will reach our targeted group in 75% (category vacc). Additionally, we also 
show results for 50% efficiency (category vacc50%). In vaccine efficiency analyses, we must look at 
longer time perspective and extend time window to 2050 for this purpose (even if we are not so sure 
about stability of model parameters and assumptions in such a long perspective).  Vaccination (with 
surveys program) strategy introduce cost of 250-300k EUR yearly. However, it’s in the beginning the 
most expensive and not the most efficient around 2020 its become cheaper than official national 
program (orange indicator) and ours (red indicator) from 2035 is more effective in terms of QALY [Figure 
22]. By introducing this program, country saves in perspective 20-35 years 1.5M EUR according to official 
program with even slightly better QALY score [Figure 23]. Moreover, comparing to realistic national 
program (yellow indicator), with almost the same budget  around 300QALY yearly will be saved. 
 
 
Figure 23 Long term cost-effectiveness analysis of main interventions. Variables (monetary and life) per year. Additionally, we 
underline 3 scenarios: our proposition (red indicator),  official national program (orange indicator), realistic realization of 
national program (yellow indicator)  
Recommendations 
Moldovan cervical cancer perspective looks much better, than in central/western Europe countries, 
because of relatively young society. In our setup, obligatory vaccination seems to not be so crucial (for 
none of realistic scenarios increase of cancer cases is possible) for public health, as in most countries in 
European Union.  
However, screening practice could be verified in terms of efficiency and cost/benefit/effectiveness  
calculation must be done. Moldova has no capacity to apply official screening (all women >20 years old) 
program (it cost more than 3M EUR yearly according to this theoretical program) called scr2. Here more 
than 700k test suppose to be done yearly (currently it’s 100k and in many sites it seems to be already 
overloaded). We propose the optimal screening guidelines (woman 25-64 old) from 2030 year  with 
prevention cost 5-12k EUR per QALY, which could provide saving perspective in range 150k-300k EUR 
yearly in respect to official program.   
We reopen re-open discussion about vaccination guidelines in low-income countries (as Moldova), 
where cost of wide action are too high. Targeted vaccination could be also consider, because costs are 
similar to high frequencies screening schema with the same cancer cases projection. We found that 
vaccination of only 20% girls chosen by surveys, will already show big difference in cancer long terms 
perspectives. We present optimal strategy: combination of our screening program and ours vaccination 
program with prevention cost 4-6k EUR per QALY from 2030.  Moreover, some positive side effects of 
vaccination as reduction of pathogen circulation in society, will cause decrease of other pathologies 
related to HPV like genital warts and other cancers. 
Supplementary information 
We model part of Moldovan population which is sexually active (15-64 years old). We assume a temporal 
naturally acquired immunity and lifelong vaccine acquired immunity, with given efficacy. Male 
population is divided in 3 stages: Susceptible (Sm), Infectious (HPVm), Recovered (Rm) and population is 
dynamic due to natural birth and death rates. For women, apart from Sw, HPVw, Rw, additional stages 
Long-term colonized (StageIIw), Vaccinated (Vw) and Having cancer (Cancer), are allowed and all except 
Cancer are divided into different age groups. We also introduced changing of society by aging, birth and 
death (which was set to affect older groups much more than younger ones). We assume that around the 
age of 65 people are not changing partners, so death rate means not natural death, but rather removing 
from sexually active society. We are still tracing women above 65, who were already infected (in age HPV 
or StageII) and can develop the cancer. We also allow dying in sexually active lifespan due to other cause, 
with age-dependent death rate. Birth, which is actually to be understood as turning 15 years and 
potentially beginning a sexual life is interpolated from register data for time up until 2014 (now) and 
extrapolated for near future. In our model, Moldovan society is slowly aging in waves (as it seems to be 
happening in reality, due to specific demographic structure). Medical properties of cancer developing are 
known to be age-dependent as well as sexual activity, so we decided to choose age groups with respect 
to data form reports. On the other hand, cancer development properties were estimated for completely 
different intervals. As a trade-off of having the smallest numbers of groups, but caching main difference 
in behavior (Age groups 1,2,3,4, +). 
Transition of disease can take place due to sexual contact with given probability. With respect to Finish 
data set, individuals in our model have a randomly chosen number of new contacts each day, which 
follows the empirical distribution for given age groups from the EEA / surveys. Stochasticity was 
introduced not at the level of individuals, but at the level of subgroup (limitation of Vensim). One can 
understand that all people in a given subgroup can be very active or passive, at different iterations. We 
introduce change of sexuality as a linear increase of newborn's sexuality (youth at age 15 coming into the 
system) during 50 years of simulation sexuality level). In the older age categories sexuality increase is 
delayed, and agents aging (coming from younger to older subgroup) have been modeled to bring their 
'sexual liberality'. 
  
Figure 24 Simplified spread of HPV by heterosexual contacts (m –for man, w – for women). Society is ‘alive’ new persons got 
birth, some die, some are aging 
Agents get temporal immunity due to natural recovery (and are moved from HPV or StageII to R), but 
after some time they lose immunity and became Susceptible (S). Moreover, recovering from HPV does 
not protect against new infections forever, even for the same strain, and other modelers assume 
immunity period of 5 or 10 years. 
Once a woman is infected, she can either recover or be "permanently" colonized. From colonized state, 
she can be screened according to the program, or for other reasons, and find out about the infection. We 
assume that disease is curable in 100% if treated at this stage. Those women at the stage StageII who 
haven't been screened have a risk of developing cancer. Once a woman has acquired cancer, she can 
either survive or die, with given probabilities. 
 
Figure 25 Cancer developing path from HPV infection through persistent colonization (Stage II) to cancer 
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